Key result
Long-acting injectable cabotegravir and rilpivirine was evaluated in a Spanish cohort of 1,366 persons with HIV, of whom 113 (8.3%) had a BMI >30 kg/m2, highlighting demographic diversity.
Demographic and geographical diversity is important when evaluating the efficacy of long-acting cabotegravir and rilpivirine in people with HIV and obesity.
To the Editor—We are writing in response to the recent paper by Maguire et al that evaluates the efficacy of long-acting injectable cabotegravir and rilpivirine (LAI-CAB + RPV) in persons with human immunodeficiency virus (HIV, PWH) who have a body mass index (BMI) > 30 kg/m2 [1]. We would like to offer some insights and comparisons between their findings and our own work in the RELATIVITY cohort (1366 PWH in 25 hospitals in Spain) [2], which has investigated LAI-CAB + RPV individuals with BMI >30 kg/m2. As of 1 April 2024, the RELATIVITY study involved 113 individuals (8.3% of the overall cohort), with a median BMI of 32.3 kg/m2 and a median age of 48 years [3]. In return, Maguire et al analyzed a cohort of 374 participants, including 148 with BMI ≥30 kg/m2 (39.5%) Their cohort was younger (median age 41 years) and had a higher representation of Black individuals (65%) compared to our cohort, with predominant Spanish and south American representation. These differences underline the importance of demographic and geographical diversity in exploring LAI-CAB + RPV outcomes.
No takes yet. Share an insight, caveat, or question.
Troya et al. (2025) conducted a letter in Human immunodeficiency virus (HIV) (n=1,366). Long-acting injectable cabotegravir and rilpivirine (LAI-CAB + RPV) was evaluated. Long-acting injectable cabotegravir and rilpivirine was evaluated in a Spanish cohort of 1,366 persons with HIV, of whom 113 (8.3%) had a BMI >30 kg/m2, highlighting demographic diversity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: